A company named Avidion is shedding light on the interactions between immune drugs and tumors, aiding scientists in pinpointing superior cell therapy candidates and gaining insights into underlying mechanisms. This development was revealed in Amsterdam on September 9, 2025. LUMICKS has introduced Avidion to the European market, representing a significant step forward in advancing scientific understanding and confidence in this field.